The Impact of Colorectal Cancer Screening on Surgical Outcomes

Colorectal Cancer Clinical Trial

Official title:

The Impact of Colorectal Cancer Screening on Surgical Outcomes

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06416501
• Other study ID #: FudanUcf
• Status: Not yet recruiting
• Start date: May 11, 2024
• Est. completion date: June 15, 2024

Study information

• Verified date: May 2024
• Source: Fudan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to investigate the pathological characteristics and surgical outcomes of stage III CRC patients detected through screening.

Data extracted from the database included the following patient information: age at diagnosis, gender, tumor location, neoadjuvant therapy, surgical procedures, histologic type, differentiation, vascular invasion, perineural invasion, pathological T stage, pathological N stage, and survival outcomes.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 4000
• Est. completion date: June 15, 2024
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients who underwent radical surgery for CRC, had confirmed stage III CRC through postoperative pathology, had no prior history of cancer before surgery, and had clear cancer detection information.

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• Prognosis
• Screening

Intervention

Other:
• Mode of detection
Mode of detection

Locations

Country	Name	City	State
China	Xinxiang Li	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival	The duration from the initial treatment to either death from any cause or the last recorded follow-up, whichever came first.; Assessed up to 100 months.	the duration from the initial treatment to either death from any cause or the last recorded follow-up, whichever came first. Assessed up to 100 months.